BRIEF published on 12/19/2025 at 12:05, 3 months 3 days ago Biotest AG Announces FDA Approval of Grifols' Fesilty™ FDA Approval Biotest AG U.S. Market Grifols Fibrinogen Therapy
PRESS RELEASE published on 12/19/2025 at 12:00, 3 months 3 days ago Biotest announces US FDA approval of Grifols’ Fesilty™ (fibrinogen, human-chmt) Biotest AG announces US FDA approval of Grifols’ Fesilty™ (fibrinogen, human-chmt) for acute bleeding episodes in patients with fibrinogen deficiency Biotest AG Fibrinogen Grifols US FDA Approval Fesilty
BRIEF published on 11/13/2025 at 10:12, 4 months 9 days ago Biotest Obtains Approval for Prufibry® in Germany Clinical Trials Biotest AG German Market Prufibry® Approval Fibrinogen Deficiency
PRESS RELEASE published on 11/13/2025 at 10:07, 4 months 9 days ago Biotest obtains approval for new human fibrinogen Prufibry® in Germany Biotest AG obtains approval in Germany for new human fibrinogen Prufibry®, expanding intensive care and coagulation factor portfolio with a life-saving therapy for congenital and acquired fibrinogen deficiency Germany Biotest AG Approval Human Fibrinogen Prufibry
BRIEF published on 11/07/2025 at 15:24, 4 months 14 days ago Biotest AG Schedules Extraordinary General Meeting at Grifols' Request Grifols S.A. Extraordinary General Meeting Biotest AG Legal Form Change Partnership Limited By Shares
PRESS RELEASE published on 11/07/2025 at 15:19, 4 months 14 days ago Biotest AG: Extraordinary general meeting convened again at the request of Grifols S.A. Biotest AG convenes an extraordinary general meeting at the request of Grifols S.A. to discuss changing its legal form to a partnership limited by shares (KGaA) on 17 December 2025 Grifols S.A. Extraordinary General Meeting Biotest AG Legal Form Change Partnership Limited By Shares
BRIEF published on 10/23/2025 at 13:21, 4 months 30 days ago Biotest AG Cancels Extraordinary General Meeting Grifols S.A. Extraordinary General Meeting Legal Form Change Corporate Restructuring Biotest AG News
PRESS RELEASE published on 10/23/2025 at 13:16, 4 months 30 days ago Biotest AG: Cancellation of the extraordinary general meeting on 28 October 2025 Biotest AG cancels extraordinary general meeting scheduled for 28 October 2025 following withdrawal of convocation request by Grifols S.A Grifols S.A. Cancellation Extraordinary General Meeting Biotest AG Legal Form Change
BRIEF published on 10/09/2025 at 17:35, 5 months 12 days ago Biotest's Yimmugo® Enters the U.S. Market Biotest AG U.S. Market Yimmugo® Launch Primary Immunodeficiencies Plasma-derived Medicines
PRESS RELEASE published on 10/09/2025 at 17:30, 5 months 12 days ago Biotest’s Yimmugo® launches in the United States Biotest AG launches Yimmugo®, a polyvalent human normal immunoglobulin (IVIg) for primary immunodeficiencies in the U.S., marking a significant milestone for the company's global growth strategy Biotest AG Yimmugo U.S. Launch Primary Immunodeficiencies IVIg
Published on 03/20/2026 at 13:30, 1 day 23 hours ago Unusual Machines Announces Pricing of Approximately $150 Million Public Offering of Common Stock
Published on 03/20/2026 at 12:30, 2 days ago CANEX Metals Announces the Numbers of Gold Basin Shares Taken up by Canex Metals
Published on 03/22/2026 at 12:23, 1 hour 5 minutes ago Borussia Dortmund and Sebastian Kehl are ending their collaboration with immediate effect
Published on 03/20/2026 at 22:45, 1 day 14 hours ago Investor Alert: Berger Montague (Canada) PC represents investors that purchased shares of Super Micro Computer, Inc. listed on the CBOE Canada and elsewhere
Published on 03/20/2026 at 21:05, 1 day 16 hours ago Fractal EMS Receives ISO/IEC 9001 and 27001 Certifications
Published on 03/20/2026 at 21:05, 1 day 16 hours ago Nebius Group announces closing of private offering of convertible senior notes, with aggregate gross proceeds of approximately $4.3 billion
Published on 03/20/2026 at 21:00, 1 day 16 hours ago BRP Unveils the Winners of its 6th International Design Challenge
Published on 03/20/2026 at 19:00, 1 day 18 hours ago AXA - Conditions for availability or consultation of information relating to AXA’s Shareholders’ Meeting of April 30, 2026
Published on 03/20/2026 at 18:15, 1 day 19 hours ago Publication of AXA’s 2025 Universal Registration Document
Published on 03/20/2026 at 16:57, 1 day 20 hours ago Number of shares and voting rights - February 2026 (In French only)
Published on 03/19/2026 at 18:00, 2 days 19 hours ago Filing of the 2025 Universal Registration Document
